

Neurinnov awarded €2.5m EIC Accelerator grant to restore hand function in patients with complete tetraplegia

Montpellier, France – 18/02/2026 – Neurinnov, a French medtech company pioneering breakthrough neurostimulation technologies, today announced it has been awarded a €2.5 million grant under the highly selective European Innovation Council (EIC) Accelerator program. This funding may be complemented by a future equity investment by the EIC Fund, subject to due process and company milestones.

The EIC Accelerator support will enable Neurinnov to accelerate the clinical, regulatory, and industrial development of its first-in-class neurostimulation device designed to restore hand function in patients with complete tetraplegia, a population for which no therapeutic solution currently exists. The program will notably support the company's path toward US and European certification and the launch of its upcoming pivotal clinical trial.

Neurinnov's technology builds on more than 15 years of research and development and relies on a proprietary microelectronic platform capable of highly selective nerve stimulation, combining 3D current injection, advanced waveform control, and patient-specific configuration. In the world-first AGILIS chronic clinical trial, patients regained the ability to grasp objects and perform everyday tasks such as eating, drinking, and brushing their teeth—unprecedented results in individuals with complete paralysis. One participant even resumed technical drawing, highlighting the technology's potential for professional reintegration.

“Our ambition is simple but transformative: to restore function, autonomy, and self-esteem to people living with severe motor loss,” said Nicolas Serandour, President of Neurinnov. “Being selected by the EIC Accelerator is a major recognition of the clinical impact, scientific excellence, and European leadership of our technology. This support will be instrumental as we move toward industrial scale-up, regulatory approval, and market access, while laying the foundations for a broader neurostimulation platform addressing multiple indications.”

Spinal cord injuries affect millions of people worldwide, many of whom remain largely invisible to society. Globally, an estimated 20 million people are living with the consequences of spinal cord injury, and in Europe and the United States alone, a new case occurs every three minutes. Within this vast and underserved population, Neurinnov initially targets more than 240,000 patients for whom there are currently no therapeutic solutions, representing individuals with the most severe forms of paralysis and the highest unmet medical need.

Beyond spinal cord injury, Neurinnov's scalable neurostimulation platform opens the door to multiple future applications, including stroke rehabilitation, bladder control, chronic pain, and vagus nerve stimulation, positioning the company as a key European player in next-generation neuroprosthetics.

About the EIC Accelerator program

The EIC Accelerator program, part of the European Union's €95 billion Horizon Europe framework program for research and innovation, supports high-risk, high-impact start-ups and SMEs developing breakthrough innovations with strong market potential. It provides a unique combination of grant funding of up to €2.5 million and equity investments via the EIC Fund, helping European innovators bridge the gap from technology to market.

Neurinnov's project is supported by a strong European clinical and scientific ecosystem, with longstanding collaborations involving INRIA, the University of Montpellier, and leading rehabilitation centers across Europe. The company has also secured letters of intent from major hospitals for its upcoming pivotal trial and is advancing industrial partnerships in preparation for scale-up.

By accelerating the development of a first-in-class solution for complete paralysis, Neurinnov aims not only to change patients' lives, but also to reinforce Europe's global leadership in restorative neurotechnologies and medical innovation.